Hepatitis B related hepatocellular carcinoma
Conditions
Interventions
Group one:PD1 + targeted drug + PEG-IFN- a- 2b(45 µ g) + nucleoside analogues
Group two:Targeted drug + PEG-IFN- a- 2b(45 µ g) + nucleoside analogues
Group three:PD1 + targeted drugs + nucleoside analogues
Group four:PD1+PEG-IFN-a-2b+Nas
Group five:Nucleoside analogues
Group six:Useless medicine
Sponsors
The First Affiliated Hospital of Xinjiang Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. The patient must sign the informed consent and voluntarily accept the follow-up for at least 48 weeks; 2. Aged 18 to 75 years, gender is not limited; 3. Patients diagnosed with stage IV in accordance with the "Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2020 Edition)" of the Chinese Society of Clinical Oncology; 4. HBsAg positive.
Exclusion criteria
Exclusion criteria: 1. Child-Pugh rating C; 2. Neutrophil count <0.5x10^9/L, or platelets <25x10^9/L; 3. A clear diagnosis of patients with anxiety or depression; 4. Pregnant women and lactating women; 5. Diabetic patients with poor blood sugar control; 6. Patients with poorly controlled hypertension and blood pressure; 7. The investigator believes that there are any other factors that are not suitable for inclusion or that affect subjects participating in or completing the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Imaging examination of liver; | — |
Secondary
| Measure | Time frame |
|---|---|
| routine blood test;liver function;Hepatitis B DNA;hepatitis B surface antigen quantification;alpha-fetoprotein; | — |
Countries
China
Contacts
Public ContactLu Xiaobo
The First Affiliated Hospital of Xinjiang Medical University
Outcome results
None listed